Selection criteria for genetic assessment of patients with familial melanoma

Journal of the American Academy of Dermatology

Volumn 61, Issue 4, 2009, Pages 677.e1-677.e14

  Leachman, Sancy A ^a   Carucci, John ^b   Kohlmann, Wendy ^a   Banks, Kimberly C ^c   Asgari, Maryam M ^d   Bergman, Wilma ^e   Bianchi Scarrà, Giovanna ^f   Brentnall, Teresa ^g   Bressac de Paillerets, Brigitte ^h   Bruno, William ^f   Curiel Lewandrowski, Clara ⁱ   de Snoo, Femke A ^e   Debniak, Tadeusz ^j   Demierre, Marie France ^k   Elder, David ^l   Goldstein, Alisa M ^m   Grant Kels, Jane ⁿ   Halpern, Allan C ^o   Ingvar, Christian ^p   Kefford, Richard F ^q   Lang, Julie ^r   MacKie, Rona M ^r   Mann, Graham J ^q   Mueller, Kurt ^s   Newton Bishop, Julia ^t   Olsson, Håkan ^p   Petersen, Gloria M ^u   Puig, Susana ^v   Rigel, Darrell ^w   Swetter, Susan M ^x   Tucker, Margaret A ^m   Yakobson, Emanuel ^y   Zitelli, John A ^z   Tsao, Hensin ^aa   more..

^a UNIVERSITY OF UTAH   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ST JOSEPH HOSPITAL   (United States)

^d DIVISION OF RESEARCH   (United States)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF GENOA   (Italy)

^g UNIVERSITY OF WASHINGTON   (United States)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ UNIVERSITY OF ARIZONA   (United States)

^j POMERANIAN MEDICAL UNIVERSITY   (Poland)

^k BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^o MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^p LUND UNIVERSITY HOSPITAL   (Sweden)

^q UNIVERSITY OF SYDNEY   (Australia)

^r UNIVERSITY OF GLASGOW   (United Kingdom)

^s GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^t UNIVERSITY OF LEEDS   (United Kingdom)

^u MAYO CLINIC   (United States)

^v INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^w NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^x STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^y TEL AVIV UNIVERSITY   (Israel)

^z UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^aa HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

CDKN2A; familial; genetic counseling; genetic testing; hereditary; melanoma; p16

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MELANOCORTIN 1 RECEPTOR; PROTEIN P14;

AUSTRALIA; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INVASION; CANCER PATIENT; COHORT ANALYSIS; CONSULTATION; DYSPLASTIC NEVUS; ETHNICITY; FAMILIAL CANCER; FAMILY HISTORY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GEOGRAPHY; HUMAN; MELANOMA; MUTATIONAL ANALYSIS; PANCREAS CANCER; PHENOTYPE; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 70249098475     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.03.016     Document Type: Review

References (96)

1. Florell S.R., Boucher K.M., Garibotti G., Astle J., Kerber R., Mineau G., et al. Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol 23 (2005) 7168-7177
2. Kefford R., Bishop J., Tucker M., Bressac-de Paillerets B., Bianchi-Scarra G., Bergman W., et al. Genetic testing for melanoma. Lancet Oncol 3 (2002) 653-654
3. Goldstein A.M., Chan M., Harland M., Hayward N.K., Demenais F., Bishop D.T., et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44 (2007) 99-106
4. Goldstein A.M., Chan M., Harland M., Gillanders E.M., Hayward N.K., Avril M.F., et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66 (2006) 9818-9828
5. Bishop D.T., Demenais F., Goldstein A.M., Bergman W., Bishop J.N., Bressac-de Paillerets B., et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94 (2002) 894-903
6. Begg C.B., Orlow I., Hummer A.J., Armstrong B.K., Kricker A., Marrett L.D., et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 97 (2005) 1507-1515
7. Goldstein A.M., Fraser M.C., Struewing J.P., Hussussian C.J., Ranade K., Zametkin D.P., et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333 (1995) 970-974
8. Vasen H.F., Gruis N.A., Frants R.R., van Der Velden P.A., Hille E.T., and Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 base pair deletion of p16 (p16-Leiden). Int J Cancer 87 (2000) 809-811
9. Parker J.F., Florell S.R., Alexander A., DiSario J.A., Shami P.J., and Leachman S.A. Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol 139 (2003) 1019-1025
10. Rulyak S.J., Brentnall T.A., Lynch H.T., and Austin M.A. Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Cancer 98 (2003) 798-804
11. Borg A., Sandberg T., Nilsson K., Johannsson O., Klinker M., Masback A., et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92 (2000) 1260-1266
12. Bartsch D.K., Sina-Frey M., Lang S., Wild A., Gerdes B., Barth P., et al. CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 236 (2002) 730-737
13. Ghiorzo P., Pastorino L., Bonelli L., Cusano R., Nicora A., Zupo S., et al. INK4/ARF germline alterations in pancreatic cancer patients. Ann Oncol 15 (2004) 70-78
14. Goldstein A.M. Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 23 (2004) 630
15. Lal G., Liu G., Schmocker B., Kaurah P., Ozcelik H., Narod S.A., et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 60 (2000) 409-416
16. Lal G., Liu L., Hogg D., Lassam N.J., Redston M.S., and Gallinger S. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. Genes Chromosomes Cancer 27 (2000) 358-361
17. Lynch H.T., Brand R.E., Lynch J.F., Fusaro R.M., Smyrk T.C., Goggins M., et al. Genetic counseling and testing for germline p16 mutations in two pancreatic cancer-prone families. Gastroenterology 119 (2000) 1756-1760
18. Lynch H.T., Brand R.E., Hogg D., Deters C.A., Fusaro R.M., Lynch J.F., et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 94 (2002) 84-96
19. Moskaluk C.A., Hruban R.H., Schutte M., Lietman A.S., Smyrk T., Fusaro L., et al. Genomic sequencing of DPC4 in the analysis of familial pancreatic carcinoma. Diagn Mol Pathol 6 (1997) 85-90
20. de Snoo F., Bishop D., Bergman W., van Leeuwen I., van der Drift C., van Nieupoort F., et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 14 (2008) 7151-7157
21. Ferrone C.R., Ben Porat L., Panageas K.S., Berwick M., Halpern A.C., Patel A., et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 294 (2005) 1647-1654
22. Ghiorzo P., Gargiulo S., Nasti S., Pastorino L., Battistuzzi L., Bruno W., et al. Predicting the risk of pancreatic cancer: on CDKN2A mutations in the melanoma-pancreatic cancer syndrome in Italy. J Clin Oncol 25 (2007) 5336-5337
23. Surveillance Epidemiology and End Results. Available from: URL:http://seercancergov/statfacts/html/melanhtml. Accessed March 1, 2008.
24. Debniak T., vad de Wetering T., Scott R., Nagay L., Cybulski C., Gorski B., et al. Low prevalence of the CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland. Eur J Cancer Prev 17 (2008) 389-391
25. Soufir N., Lacapere J.J., Bertrand G., Matichard E., Meziani R., Mirebeau D., et al. Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma. Br J Cancer 90 (2004) 503-509
26. Youl P., Aitken J., Hayward N., Hogg D., Liu L., Lassam N., et al. Melanoma in adolescents: a case-control study of risk factors in Queensland, Australia. Int J Cancer 98 (2002) 92-98
27. Nagore E., Montoro A., Oltra S., Ledesma E., Botella-Estrada R., Millan J.M., et al. Age does not appear to be a major indicator of CDKN2A or CDK4 mutations in melanoma patients in Spain. Melanoma Res 15 (2005) 555-558
28. Berg P., Wennberg A.M., Tuominen R., Sander B., Rozell B.L., Platz A., et al. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Res 14 (2004) 251-255
29. Tsao H., Zhang X., Kwitkiwski K., Finkelstein D.M., Sober A.J., and Haluska F.G. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 136 (2000) 1118-1122
30. Stratigos A.J., Yang G., Dimisianos R., Nicolaou V., Stefanaki I., Katsambas A.D., et al. Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma. J Invest Dermatol 126 (2006) 399-401
31. Whiteman D.C., Milligan A., Welch J., Green A.C., and Hayward N.K. Germline CDKN2A mutations in childhood melanoma. J Natl Cancer Inst 89 (1997) 1460
32. Lynch H.T., Frichot B.C., and Lynch J.F. Familial atypical multiple mole-mapping syndrome. J Med Genet 15 (1978) 352-356
33. Slade J., Salopek T.G., Marghoob A.A., Kopf A.W., and Rigel D.S. Risk of developing cutaneous malignant melanoma in atypical-mole syndrome: New York University experience and literature review. Recent Results Cancer Res 139 (1995) 87-104
34. Kopf A.W., Friedman R.J., and Rigel D.S. Atypical mole syndrome. J Am Acad Dermatol 22 (1990) 117-118
35. Carey Jr. W.P., Thompson C.J., Synnestvedt M., Guerry D.T., Halpern A., Schultz D., et al. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer 74 (1994) 3118-3125
36. Gruis N.A., Sandkuijl L.A., van der Velden P.A., Bergman W., and Frants R.R. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res 5 (1995) 169-177
37. Wachsmuth R.C., Harland M., and Bishop J.A. The atypical-mole syndrome and predisposition to melanoma. N Engl J Med 339 (1998) 348-349
38. Goldstein A.M., Martinez M., Tucker M.A., and Demenais F. Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families. Cancer Epidemiol Biomarkers Prev 9 (2000) 889-894
39. Bishop J.A., Wachsmuth R.C., Harland M., Bataille V., Pinney E., Mack K.P., et al. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol 114 (2000) 28-33
40. Florell S.R., Meyer L.J., Boucher K.M., Hart M., Cannon-Albright L.A., Harris R.M., et al. Nevus distribution in a Utah melanoma kindred with a temperature-sensitive CDKN2A mutation. J Invest Dermatol 125 (2005) 1310-1312
41. Celebi J.T., Ward K.M., Wanner M., Polsky D., and Kopf A.W. Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome. Clin Exp Dermatol 30 (2005) 68-70
42. Ung-Juurlink C. American Academy of Dermatology 1999 awards for young investigators in dermatology: the prevalence of CDKN2A in patients with atypical nevi and malignant melanoma. J Am Acad Dermatol 41 (1999) 461-462
43. Matsumura Y., Nishigori C., and Miyachi Y. Analysis of the p16 gene status of non-familial dysplastic nevus syndrome patients. Arch Dermatol Res 293 (2001) 540-542
44. de Snoo F.A., Kroon M.W., Bergman W., ter Huurne J.A., Houwing-Duistermaat J.J., van Mourik L., et al. From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in sporadic atypical nevus patients. J Am Acad Dermatol 56 (2007) 748-752
45. Box N.F., Duffy D.L., Chen W., Stark M., Martin N.G., Sturm R.A., et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 69 (2001) 765-773
46. Goldstein A.M., Chaudru V., Ghiorzo P., Badenas C., Malvehy J., Pastorino L., et al. Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries. Int J Cancer 121 (2007) 825-831
47. GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1993-2009. Available at http://www.genetests.org. Accessed September 1, 2008.
48. American Society of Clinical Oncology policy statement update. genetic testing for cancer susceptibility. J Clin Oncol 21 (2003) 2397-2406
49. Aspinwall L., Leaf S., Dola E., Kohlmann W., and Leachman S. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. Cancer Epidemiol Biomarkers Prev 17 (2008) 1510-1519
50. Hadley D.W., Jenkins J.F., Dimond E., de Carvalho M., Kirsch I., and Palmer C.G. Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 22 (2004) 39-44
51. Botkin J.R., Smith K.R., Croyle R.T., Baty B.J., Wylie J.E., Dutson D., et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 118 (2003) 201-209
52. Lamperska K., Karezewska A., Kwiatkowska E., and Mackiewicz A. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population. Acta Biochim Pol 49 (2002) 369-376
53. Fitzgerald M.G., Harkin D.P., Silva-Arrieta S., MacDonald D.J., Lucchina L.C., Unsal H., et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A 93 (1996) 8541-8545
54. MacKie R.M., Andrew N., Lanyon W.G., and Connor J.M. CDKN2A germline mutations in UK patients with familial melanoma and multiple primary melanomas. J Invest Dermatol 111 (1998) 269-272
55. Soufir N., Avril M.F., Chompret A., Demenais F., Bombled J., Spatz A., et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France: the French familial melanoma study group. Hum Mol Genet 7 (1998) 209-216
56. Holland E.A., Schmid H., Kefford R.F., and Mann G.J. CDKN2A (p16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer 25 (1999) 339-348
57. Newton-Bishop J.A., Harland M., Bennett D.C., Bataille V., Goldstein A.M., Tucker M.A., et al. Mutation testing in melanoma families: INK4A, CDK4 and INK4D. Br J Cancer 80 (1999) 295-300
58. Harland M., Meloni R., Gruis N., Pinney E., Brookes S., Spurr N.K., et al. Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6 (1997) 2061-2067
59. Ruiz A., Puig S., Malvehy J., Lazaro C., Lynch M., Gimenez-Arnau A.M., et al. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. J Med Genet 36 (1999) 490-493
60. Yakobson E., Shemesh P., Azizi E., Winkler E., Lassam N., Hogg D., et al. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. Eur J Hum Genet 8 (2000) 590-596
61. Della Torre G., Pasini B., Frigerio S., Donghi R., Rovini D., Delia D., et al. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer 85 (2001) 836-844
62. Alao J.P., Mohammed M.Q., and Retsas S. The CDKN2A tumor suppressor gene: no mutations detected in patients with melanoma and additional unrelated cancers. Melanoma Res 12 (2002) 559-563
63. Mantelli M., Barile M., Ciotti P., Ghiorzo P., Lantieri F., Pastorino L., et al. High prevalence of the G101W germline mutation in the CDKN2A (p16(INK4a)) gene in 62 Italian malignant melanoma families. Am J Med Genet 107 (2002) 214-221
64. Chaudru V., and Chompret A. Bressac-de Paillerets B, Spatz A, Avril MF, Demenais F. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 96 (2004) 785-795
65. Debniak T., Gorski B., Scott R.J., Cybulski C., Medrek K., Zowocka E., et al. Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer. Int J Cancer 110 (2004) 558-562
66. Landi M.T., Goldstein A.M., Tsang S., Munroe D., Modi W., Ter-Minassian M., et al. Genetic susceptibility in familial melanoma from northeastern Italy. J Med Genet 41 (2004) 557-566
67. Lang J., Boxer M., and MacKie R.M. CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families. Br J Dermatol 153 (2005) 1121-1125
68. Marian C., Scope A., Laud K., Friedman E., Pavlotsky F., Yakobson E., et al. Search for germline alterations in CDKN2A/ARF and CDK4 of 42 Jewish melanoma families with or without neural system tumors. Br J Cancer 92 (2005) 2278-2285
69. Eliason M.J., Larson A.A., Florell S.R., Zone J.J., Cannon-Albright L.A., Samlowski W.E., et al. Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol 126 (2006) 660-666
70. Hocevar M., Avbelj M., Peric B., Zgajnar J., Besic N., and Battelino T. High prevalence of germline CDKN2A mutations in Slovenian cutaneous malignant melanoma families. Croat Med J 47 (2006) 851-854
71. Huber J., and Ramos E.S. The P48T germline mutation and polymorphism in the CDKN2A gene of patients with melanoma. Braz J Med Biol Res 39 (2006) 237-241
72. Niendorf K.B., Goggins W., Yang G., Tsai K.Y., Shennan M., Bell D.W., et al. MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. J Med Genet 43 (2006) 501-506
73. Kamb A., Shattuck-Eidens D., Eeles R., Liu Q., Gruis N.A., Ding W., et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8 (1994) 23-26
74. Platz A., Hansson J., Mansson-Brahme E., Lagerlof B., Linder S., Lundqvist E., et al. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 89 (1997) 697-702
75. Fargnoli M.C., Chimenti S., Keller G., Soyer H.P., Dal Pozzo V., Hofler H., et al. CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds. J Invest Dermatol 111 (1998) 1202-1206
76. Liu L., Dilworth D., Gao L., Monzon J., Summers A., Lassam N., et al. Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21 (1999) 128-132
77. Mantelli M., Pastorino L., Ghiorzo P., Barile M., Bruno W., Gargiulo S., et al. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients. Melanoma Res 14 (2004) 443-448
78. Casula M., Colombino M., Satta M.P., Cossu A., Lissia A., Budroni M., et al. Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. Eur J Cancer 43 (2007) 137-143
79. Flores J.F., Pollock P.M., Walker G.J., Glendening J.M., Lin A.H., Palmer J.M., et al. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene 15 (1997) 2999-3005
80. Aitken J., Welch J., Duffy D., Milligan A., Green A., Martin N., et al. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 91 (1999) 446-452
81. Monzon J., Liu L., Brill H., Goldstein A.M., Tucker M.A., From L., et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 338 (1998) 879-887
82. Hashemi J., Platz A., Ueno T., Stierner U., Ringborg U., and Hansson J. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res 60 (2000) 6864-6867
83. Auroy S., Avril M.F., Chompret A., Pham D., Goldstein A.M., Bianchi-Scarra G., et al. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer 32 (2001) 195-202
84. Blackwood M.A., Holmes R., Synnestvedt M., Young M., George C., Yang H., et al. Multiple primary melanoma revisited. Cancer 94 (2002) 2248-2255
85. Peris K., Fargnoli M.C., Pacifico A., Surrenti T., Stolz W., Wolf P., et al. CDKN2A and MC1R mutations in patients with sporadic multiple primary melanoma. J Invest Dermatol 122 (2004) 1327-1330
86. Puig S., Malvehy J., Badenas C., Ruiz A., Jimenez D., Cuellar F., et al. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 23 (2005) 3043-3051
87. Nielsen K., Ingvar C., Masback A., Westerdahl J., Borg A., Sandberg T., et al. Melanoma and nonmelanoma skin cancer in patients with multiple tumors-evidence for new syndromes in a population-based study. Br J Dermatol 150 (2004) 531-536
88. Rutter J.L., Bromley C.M., Goldstein A.M., Elder D.E., Holly E.A., Guerry D.T., et al. Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study. Cancer 101 (2004) 2809-2816
89. Gerdes B., Bartsch D.K., Ramaswamy A., Kersting M., Wild A., Schuermann M., et al. Multiple primary tumors as an indicator for p16INK4a germline mutations in pancreatic cancer patients?. Pancreas 21 (2000) 369-375
90. Austin M.A., Bowen D.J., Burke w., Fishbach A., Fesinmeyer M.D., and Potter J.D. Pilot study of BRCA2 and CDKN2A mutations among pancreatic cancer cases in the Northwest cancer genetics network (November 7-9, 2003), Poster presented at: Fourth International Symposium on Inherited Diseases of the Pancreas, Chicago (IL)
91. Prowse A.H., Schultz D.C., Guo S., Vanderveer L., Dangel J., Bove B., et al. Identification of a splice acceptor site mutation in p16INK4A/p14ARF within a breast cancer, melanoma, neurofibroma prone kindred. J Med Genet 40 (2003) e102
92. Moskaluk C.A., Hruban H., Lietman A., Smyrk T., Fusaro L., Fusaro R., et al. Novel germline p16(INK4) allele (Asp145Cys) in a family with multiple pancreatic carcinomas: mutations in brief No. 148. Hum Mutat 12 (1998) 70
93. Burden A.D., Newell J., Andrew N., Kavanagh G., Connor J.M., and MacKie R.M. Genetic and environmental influences in the development of multiple primary melanoma. Arch Dermatol 135 (1999) 261-265
94. Ghiorzo P., Ciotti P., Mantelli M., Heouaine A., Queirolo P., Rainero M.L., et al. Characterization of Ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 83 (1999) 441-448
95. Goldstein A.M., Struewing J.P., Chidambaram A., Fraser M.C., and Tucker M.A. Genotype-phenotype relationships in US melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 92 (2000) 1006-1010
96. de Vos tot Nederveen Cappel W.H., Offerhaus G.J., van Puijenbroek M., Caspers E., Gruis N.A., De Snoo F.A., et al. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden). Clin Cancer Res 9 (2003) 3598-3605